8-K: Tenax Therapeutics Secures $100 Million in Private Placement to Accelerate Phase 3 Program

Tenax Therapeutics has successfully closed a $100 million private placement, which will be used to accelerate the development of its oral levosimendan program for pulmonary hypertension due to heart failure with preserved ejection fraction.

Summary

• Tenax Therapeutics has closed a private placement, raising approximately $100 million in gross proceeds.
• The funding will primarily support the advancement of the oral levosimendan (TNX-103) Phase 3 development program.
• This includes the completion of the ongoing LEVEL study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF).
• The proceeds will also fund the initiation of a second Phase 3 study planned for 2025, aiming to shorten the timeline to NDA submission.
• The company plans to submit the protocol for the second Phase 3 study to the FDA for comment.
• The private placement involved the issuance of 1,450,661 shares of common stock and pre-funded warrants to purchase 31,882,671 shares, along with accompanying warrants for 16,666,666 shares.
• The purchase price for each share and accompanying warrant was $3.00, with the warrant having an exercise price of $4.50.
• Pre-funded warrants were priced at $2.99 with an exercise price of $0.01.
• The company has agreed to file a registration statement with the SEC for the resale of the shares within 30 days of the closing.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the successful capital raise, the acceleration of the Phase 3 program, and the promising clinical results of levosimendan. The involvement of top-tier investors further boosts the positive outlook.

Positives

• The successful $100 million private placement provides significant funding for the company's clinical programs.
• The oversubscribed nature of the private placement indicates strong investor confidence in the company and its lead drug candidate.
• The funding will enable the company to accelerate its Phase 3 program and potentially shorten the time to NDA submission.
• Levosimendan has shown promising results in improving exercise capacity in patients with PH-HFpEF, a condition with no approved therapies.
• The company has secured funding through the completion of the ongoing Phase 3 LEVEL study, including its open label extension.

Negatives

• The securities issued in the private placement have not been registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption.
• The accompanying warrants expire upon the earlier of 30 trading days following the announcement of topline data from the Phase 3 LEVEL trial, the exercise of the pre-funded warrants, or five years from the closing date.

Risks

• The company's actual results may differ materially from forward-looking statements due to various factors.
• These factors include the expected use of proceeds, cash runway, business strategy, clinical trial risks, regulatory delays, reliance on third parties, and market acceptance of product candidates.
• There are risks related to the company's continued listing on Nasdaq and its ability to maintain its culture and retain qualified personnel.
• Global economic and financial uncertainties, including geopolitical issues, could impact the company's operations.
• Changes in legal, regulatory, and legislative environments could affect the company's ability to obtain regulatory approval for its products.

Future Outlook

The company plans to use the proceeds to complete the ongoing Phase 3 LEVEL study and initiate a second Phase 3 study in 2025, aiming to shorten the timeline to NDA submission. They also plan to submit the protocol for the second Phase 3 study to the FDA for comment.

Management Comments

• Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics, stated that the financing is a significant commitment by top-tier biotech investors who believe in levosimendan's potential.
• He also mentioned that the proceeds position the company to accelerate its Phase 3 development program and shorten the time to NDA submission.
• Stuart Rich, MD, Chief Medical Officer of Tenax Therapeutics, noted that patients showed further improvement in exercise capacity when transitioned from weekly IV to oral daily therapy.

Industry Context

This announcement is significant in the context of the pharmaceutical industry, particularly for companies focused on cardiovascular and pulmonary diseases. The successful private placement and the advancement of levosimendan could position Tenax Therapeutics as a key player in the treatment of PH-HFpEF, a condition with high unmet medical need. The company is targeting a market with no approved therapies, which could lead to significant market share if successful.

Comparison to Industry Standards

• The 10% improvement in the six-minute walk distance observed in the HELP study is a notable result, as no other drug therapy has shown improvement in exercise tolerance in patients with PH associated with HFpEF.
• The company's focus on oral levosimendan is a strategic move, as it offers a more convenient administration route compared to intravenous options, which are common in the treatment of heart failure.
• The involvement of top-tier biotech investors like BVF Partners LP, Venrock Healthcare Capital Partners, and Vivo Capital indicates a strong validation of the company's technology and potential.
• The company's plan to initiate a second Phase 3 study in 2025 is aggressive and demonstrates a commitment to bringing the therapy to market quickly.

Stakeholder Impact

• Shareholders will benefit from the increased funding and accelerated development of levosimendan.
• Patients with PH-HFpEF may have access to a new treatment option if the clinical trials are successful.
• Employees may experience increased job security and growth opportunities due to the company's progress.
• The company's suppliers and partners may benefit from increased business activity.

Next Steps

• The company will complete the ongoing Phase 3 LEVEL study.
• They will initiate a second Phase 3 study in 2025.
• The company will submit the protocol for the second Phase 3 study to the FDA for comment.
• Tenax Therapeutics will file a registration statement with the SEC for the resale of the shares issued in the private placement within 30 days.

Key Dates

Keywords

levosimendan, pulmonary hypertension, heart failure, private placement, Phase 3, TNX-103, PH-HFpEF, clinical trial, NDA, exercise capacity